Original language | English (US) |
---|---|
Pages (from-to) | 728-730 |
Number of pages | 3 |
Journal | The Lancet |
Volume | 388 |
Issue number | 10045 |
DOIs |
|
State | Published - Aug 13 2016 |
Bibliographical note
Funding Information:JF is the director at the Wellcome Trust. FTC reports personal fees from the Bill & Melinda Gates Foundation, during the completion of this Personal View. NEB reports grants from the US National Institutes of Health (NIH) Director's Early Independence Award (number DP5OD009162), during the completion of this Personal View. NMF reports grants from the UK Medical Research Council, NIH National Institute of General Medical Sciences, Bill & Melinda Gates Foundation, and the UK NIH Research, during the completion of this Personal View. DSB reports travel reimbursements from Sanofi Dengue Vaccine Company, outside the submitted Personal View. DSB has a Provisional Patent Application (USA) for: new serological tests for HIV based on binding to biologically inspired non-biological chemical entities. CJEM, JL, and BTG report grants from the Bill & Melinda Gates Foundation. ALG declares no competing interests.
Funding Information:
We thank the Bill & Melinda Gates Foundation, the RAPIDD programme of the Science and Technology Directorate Department of Homeland Security and the Fogarty International Centre, National Institutes of Health (NIH), UK Medical Research Council, NIH National Institute of General Medical Sciences, and UK NIH Research for their financial support.